Trial Profile

A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary)
Indications Advanced breast cancer; Colorectal cancer; Fallopian tube cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Biomarker

Most Recent Events

01 Mar 2012 Actual patient number (8) added as reported by ClinicalTrials.gov.
27 Feb 2012 Biomarkers information updated
23 Feb 2012 Planned End Date changed from 1 Nov 2017 to 1 Aug 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com